Evidence map›Paper›PMID 27714651›Full record

ArticleJournal of gastrointestinal cancer2017

Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.

Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Celaletdin Camci

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tulay KusDepartment of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, 27310, Gaziantep, TR, Turkey. drtulaykus83@hotmail.com.
Gokmen AktasDepartment of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, 27310, Gaziantep, TR, Turkey.
Mehmet Emin KalenderDepartment of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, 27310, Gaziantep, TR, Turkey.
Alper SevincDepartment of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, 27310, Gaziantep, TR, Turkey.
Celaletdin CamciDepartment of Internal Medicine, Division of Medical Oncology, University of Gaziantep, Gaziantep Oncology Hospital, 27310, Gaziantep, TR, Turkey.
Gaziantep University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this retrospective study was to compare the different treatment options of patients with advanced biliary tract carcinoma (BTC) who were treated with platinum-gemcitabine (CG) or platinum-5-fluorouracil (CF) or 5-Fluorouracil-oxaliplatin-irinotecan (FOLFIRINOX) chemotherapy.

methodsWe included the patients with advanced BTC who were registered at the Department of Oncology in Gaziantep University between January 2008 and January 2016. The following data were analyzed: disease control rate (DCR), progression free survival (PFS) of first and second-line of chemotherapy, and overall survival (OS). Kaplan-Meier method and Log-rank test was used to compare two survival curves, and hazard regression model was used to evaluate risk factors for PFS.

resultNinety-two patients were recruited. 53 (57.6 %), 27 (29.3 %), and 12 (13 %) patients received CG, CF, and FOLFIRINOX regimen as first-line chemotherapy, respectively. Median PFS and DCR of CG group were 22 weeks and 56.6 %, and these were 12 weeks and 44.4 % for CF group, and 9 weeks and 41.7 % for FOLFIRINOX group. Median OS of CG, CF, and FOLFIRINOX groups was 28, 21,and 23.5 weeks, respectively (p = 0.497). Second-line PFS of fluoropyrimidine-based chemotherapy group and gemcitabine-based chemotherapy group was 12 vs. 14 weeks (p = 0.988). Second-line PFS of FOLFIRINOX was 20 weeks, whereas it was 14 weeks for other fuoropyrimidine-based chemotherapies (p = 0.190).

conclusionsThis was the first study evaluating the FOLFIRINOX regimen in BTC. Cisplatin-gemcitabine therapy still provides better survival in BCT. However, FOLFIRINOX can be an option in the second-line treatment of BTC patients who are eligible for chemotherapy.

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsCarcinomaDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeAntineoplastic AgentsAdvanced biliary tract cancerCisplatinFluoropyrimidineFOLFIRINOXGemcitabineSecond-line chemotherapy

Identifiers

PMID27714651
OpenAlexW2529833897

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.